Denosumab (120 mg – sub-cutaneous) is a therapy molecule to reduce and delay Skeletal Related Events (“SREs”) across solid tumours and multiple myeloma
Ahmedabad: Zydus Lifesciences Ltd., an innovation-led healthcare company, with an international presence has launched ‘Zyrifa’, a Denosumab biosimilar. Denosumab is a monoclonal antibody with several indications related to bone health, primarily in the treatment of osteoporosis and the prevention of skeletal complications in cancer patients. This will provide access and treat patients with bone metastases due to breast, prostate, lung, myeloma, kidney, thyroid, head & neck, and other solid tumours. Metastases, is when the cancer spreads to the bones and other organs in the body indicating an advanced stage of cancer. ‘Zyrifa’ is priced at MRP of Rs 12,495.
Bone metastases are a serious complication across multiple cancers, significantly impacting patient quality of life. Patients experience pain, fractures, spinal cord compression, reduced mobility, and loss of independence, often impacting their dignity and increasing mortality risk. The condition most commonly affects the axial skeleton (spine, pelvis, ribs), leading to severe complications.
Speaking on this launch, Dr. Sharvil P. Patel, Managing Director, Zydus Lifesciences Limited., said “With Denosumab 120 mg SC, we aim to bring access, affordability of medication in cancer patients needing critical care. This will help patients to retain mobility, and support them in their fight against cancer”
Population scale analyses and registry studies consistently show high bone involvement rates in advanced disease; in advanced breast or prostate cancer, bone involvement affects 50 -70% of patients, whereas 15-40% of lung, kidney, thyroid, and melanoma cases also develop skeletal metastases over time.
Zydus Lifesciences Limited has been launching a wide range of biosimilars to treat various cancers ranging from breast cancer to prostate cancer, various other solid tumours and blood cancer. The company has also partnered with diagnostic companies.
